Showing results (81-90 of 118) with videos related to
Sort By:
Pageof 12
JCI Insight|February 28, 2017
Switching harmful visceral fat to beneficial energy combustion improves metabolic dysfunctionsXiaoyan Yang, Wenhai Sui, Meng Zhang, et al.Cancer Medicine|May 21, 2024
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysisJing Gao, Yan Song, Xiaoge Kou, et al.Ebiomedicine|June 25, 2026
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumoursHerui Yao, Ruihua Zhao, Xiuping Lai, et al.Nature Medicine|February 2, 2023
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trialYan Song, Bo Zhang, Dao Xin, et al.Med (New York, N.Y.)|June 13, 2024
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trialZi-Xian Wang, Junjie Peng, Xinjun Liang, et al.The Lancet. Respiratory Medicine|May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.Signal Transduction and Targeted Therapy|July 27, 2025
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS<sup>G12C</sup> inhibitor-naïve Chinese patients with KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studiesYing Yuan, Yanhong Deng, Yongdong Jin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.The Lancet. Oncology|July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.BMC Medicine|December 19, 2024
Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort studyXue Zhang, Xin Dai, Aina Liu, et al.Pageof 12